Mechanism of Action, Preclinical Efficacy, and Safety Evaluation of ACP-711 (SAN711): A Novel GABAA Subunit α3 Selective Modulator (P8-17.012)

Dipak V. Amrutkar; Karin Sandager‐Nielsen; Tino Dyhring; Thomas A. Jacobsen; Janus S. Larsen; Pierandrea Muglia; Sanjeev Pathak; Hank Lin; Robert Hofbauer

doi:10.1212/wnl.0000000000215282

June 9, 2026Neurology

Mechanism of Action, Preclinical Efficacy, and Safety Evaluation of ACP-711 (SAN711): A Novel GABAA Subunit α3 Selective Modulator (P8-17.012)

View at Publisher

Ask AI

Bookmark

Share

Key Points

The research aims to evaluate the pharmacological properties and safety of ACP-711 in preclinical models of essential tremor.
Conducted in vitro pharmacological assessments of ACP-711.
Evaluated efficacy in preclinical animal models specifically for essential tremor.
Assessed adverse effects associated with ACP-711 administration.
ACP-711 demonstrated significant efficacy in reducing tremor symptoms in animal models.
The safety evaluation revealed a manageable profile of adverse effects with ACP-711 treatment.
Results indicate a promising mechanism of action for targeting GABAA α3 subunits.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Preclinical evaluation shows ACP-711 improves outcomes in essential tremor, indicating potential therapeutic use.

Abstract

Evaluate the pharmacology, efficacy, and adverse effects (AEs) of ACP-711 (SAN711) in vitro and in preclinical animal models of essential tremor (ET).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Amrutkar et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf36efaef96ed7f055df7 https://doi.org/10.1212/wnl.0000000000215282

View at Publisher

Ask AI

Bookmark

Share

Mechanism of Action, Preclinical Efficacy, and Safety Evaluation of ACP-711 (SAN711): A Novel GABAA Subunit α3 Selective Modulator (P8-17.012)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Mechanism of Action, Preclinical Efficacy, and Safety Evaluation of ACP-711 (SAN711): A Novel GABAA Subunit α3 Selective Modulator (P8-17.012)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading